PRESS RELEASE |

NAXUS®    Results of a randomized controlled trial on reinforcement of intestinal epithelial barrier by arabinoxylans in overweight and obese subjects published in high impact journal.

 

The Clinical Nutrition Journal has published the results of the latest clinical study on the effect of arabinoxylans on gut barrier. NAXUS® is a clinically evaluated wheat arabinoxylan concentrate produced by BioActor BV for the support of digestive health. The article concludes that “regular consumption of arabinoxylans results in a more beneficial fermentation profile in overweight and obese individuals.” Such a fermentation profile may lead to improved gut barrier function and immune health.

Maastricht, Netherlands, March 8, 2017

In a randomized, double-blind, placebo-controlled study the effect of 6-weeks daily intake of 7.5g or 15g arabinoxylans, supplied as Naxus® by BioActor BV, on intestinal permeability was evaluated.

Obesity and metabolic diseases are associated with alterations in microbial composition and impaired gut barrier. The aims of the study were to investigate the effect of Naxus® on intestinal permeability, on gene transcription and protein expression of tight junctions, intestinal microbiota composition and activity, immune response and metabolic markers in overweight and obese individuals. Modulating gut microbiota composition, which influences its effect on intestinal homeostasis, appears to be a promising strategy to treat and prevent chronic diseases.

 

Gut biopsy specimens showed an upregulation of gene transcription of tight junction and associated proteins in both the 7.5g and 15g Naxus® group compared to placebo. Moreover, intake of Naxus® significantly decreased fecal pH and increased fecal concentrations of total short-chain fatty acids (SCFAs), acetate, propionate and butyrate, compared to placebo

 

In conclusion, regular consumption of Naxus® resulted in a more beneficial fermentation, i.e. SCFA,  profile in overweight and obese individuals. Such a fermentation profile could translate into improved gut barrier function and immune health. Furthermore, an increased gene transcription of several transmembrane proteins was observed. Finally it was shown that 15g Naxus® might have an anti-inflammatory potential and the intake of Naxus® is well-tolerated.

 

Further information can be found on: www.bioactor.com/products.

About BioActor

BioActor, based on the Health Campus at Maastricht, Netherlands, is a life sciences company that develops and supplies proprietary health ingredients to the nutrition & healthcare industry. The company focuses on the clinical development of innovative bioactives that address ageing related chronic health conditions and support active living. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer clinically proven health benefits to the consumer.

For further information about BioActor, see www.bioactor.com or contact Hans van der Saag, Managing Director, on + 31 43 711 4555, or mail to: hans.vandersaag@bioactor.com